<DOC>
	<DOCNO>NCT01199822</DOCNO>
	<brief_summary>Participants single-center , open-label , dose-escalation , Phase 1 study initially receive intravenous ( I.V . ) IMC-3G3 every 2 week Days 1 8 every 3 week 6 week ( one cycle ) . After first cycle , patient experience overall response complete response ( CR ) , partial response ( PR ) , stable disease ( SD ) continue receive IMC-3G3 cohort dose schedule evidence progressive disease ( PD ) , withdrawal criterion meet .</brief_summary>
	<brief_title>Study Safety Pharmacokinetics IMC-3G3 Japanese Patients With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Solid tumor histopathologically cytologically document Advanced primary recurrent solid tumor patient respond standard therapy standard therapy available Measurable nonmeasurable lesion An Eastern Cooperative Oncology Group performance status score 01 Able provide inform consent Has life expectancy &gt; 3 month Adequate hematologic function Adequate hepatic function Has adequate renal function Agrees use adequate contraception duration study participation least 12 week last dose study therapy Adequate recovery recent surgery , chemotherapy , radiation therapy ( include palliative radiation therapy ) . At least 28 day ( 6 week nitrosoureas mitomycin C ) must elapse major surgery , prior chemotherapy , prior treatment investigational agent device , prior radiation therapy . For treatment nonapproved monoclonal antibody , minimum 8 week must elapse Is willing comply study procedure EndofTherapy visit Received chemotherapy therapeutic radiotherapy within 28 day ( 6 week nitrosoureas mitomycin C ) prior enter study , ongoing side effect ≥ Grade 2 due agent administer 28 day earlier Has undergone major surgery ( eg , laparotomy , thoracotomy , removal organ [ ] ) within 28 day prior study entry Elective plan surgery conduct trial Documented and/or symptomatic brain leptomeningeal metastasis ( patient clinically stable [ symptom 4 week prior study entry ] assessment treatment [ radiation , surgical excision , administration steroid ] require permitted enter study ) Uncontrolled intercurrent illness include , limited : Active infection require systemic antibiotic treatment exclude oral administration ( ≥ Grade 3 [ NCICTCAE Version 4.02 ] ) Congestive heart failure ( Class III IV per New York Heart Association classification heart disease ) Angina pectoris , angioplasty , stenting , myocardial infarction within 6 month Uncontrolled hypertension ( systolic blood pressure &gt; 150 mm Hg , diastolic blood pressure &gt; 95 mm Hg ) Cardiac arrhythmia require treatment ( National Cancer Institute Common Terminology , asymptomatic sustain ventricular tachycardia Peripheral neuropathy etiology ≥ Grade 2 ( NCICTCAE Version 4.02 ) ; Any serious uncontrolled medical disorder ( ) opinion investigator Participated clinical study nonapproved experimental agent procedure within 4 week prior study small molecule , 8 week prior study entry nonapproved monoclonal antibody Received previous treatment agent target PDGF PDGFR , approve nonapproved Known allergy treatment component ( IMC3G3 , histidine , glycine , sodium chloride , mannitol , polysorbate ) If female , pregnant ( confirmed urine serum pregnancy test ) lactate Known alcohol drug dependency Hepatitis B virus ( HBV ) antigen , hepatitis C virus ( HCV ) antibody , human immunodeficiency ( HIV ) antibodypositive ( asymptomatic healthy carrier detectable HBVDNA , HCVRNA may enrol trial ) Assessed inadequate study investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>